Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Martin E. Swarbrick et al.|Nature Communications|2021Cited by 358
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancerNirmesh Patel, Andrew Tutt, Daniel Weekes et al.|Nature Communications|2018Cited by 57
Abstract P056: Polθ inhibitors elicit <i>BRCA</i>-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Christopher J. Lord, Helen M.R. Robinson et al.|Molecular Cancer Therapeutics|2021Cited by 3
Abstract 5697: Targeting PARP inhibitor resistance with Polθ inhibitorsDiana Zatreanu, Christopher J. Lord, Helen M. Robinson et al.|Cancer Research|2022Cited by 1
Abstract 67: An integrated copy number and gene expression genomics analysis and RNAi approach identifies and validates the KIFC1 kinesin as a malignant cell selective target in triple negative breast cancerNirmesh Patel, Andrew Tutt, Κωνσταντίνος Δροσόπουλος et al.|Cancer Research|2016Cited by 0